Á¦ 2Â÷ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°Á : 2022-01-22±³À°ÀÏÀÚ : 2022-01-22
±³À°Àå¼Ò : (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) °æ±âµµ ¾È¾ç ÇѸ²´ëÇб³¼º½Éº´¿ø ½Ã¹Ä·¹ÀÌ¼Ç ¼¾ÅÍ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) Á¦ 2Â÷ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬±¸È¸
´ã´çÀÚ : ÀÓ¼±È
¿¬¶ôó : 031-380-3976
À̸ÞÀÏ :
karai.secretary@gmail.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
°æ±âµµ±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ-2¸¸¿ø/ ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç-1¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 01-22 ½Ã¹Ä·¹À̼Ǽ¾ÅÍ 09:10~09:45 Anemia and Iron deficiency in children with CKD À̱ÝÈ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 01-22 ½Ã¹Ä·¹À̼Ǽ¾ÅÍ 09:45~10:20 Erythropoietin administration: Route and Outcome ±èµµÇü(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 01-22 ½Ã¹Ä·¹À̼Ǽ¾ÅÍ 10:35~11:10 HIF prolyl-hydroxylase inhibitors : Expectations and Concerns ÁöÁ¾Çö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 01-22 ½Ã¹Ä·¹À̼Ǽ¾ÅÍ 11:10~11:45 Novel Iron therapies for anemia in CKD patients ¹ÚÀçÀ±(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 01-22 ½Ã¹Ä·¹À̼Ǽ¾ÅÍ 11:45~12:25 Medium cut-off dialyzer and resistance of erythropoiesis stimulating agent ÀÓÁ¤ÈÆ(°æºÏÀÇ´ë)